Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
<p>Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.</p>
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Άλλοι συγγραφείς: | , , , , , , , , , , , , , , , , , , |
| Έκδοση: |
2025
|
| Θέματα: | |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
| _version_ | 1849927633725292544 |
|---|---|
| author | Martina S.J. McDermott (15206951) |
| author2 | Neil A. O'Brien (15206954) Benjamin Hoffstrom (15206957) KeWei Gong (15206960) Ming Lu (15206963) Jun Zhang (15206966) Tong Luo (15206969) Min Liang (15206972) Weiping Jia (15206975) Jenny J. Hong (15206978) Kevin Chau (15206981) Simon Davenport (15206984) Bin Xie (15206987) Michael F. Press (15206990) Richard Panayiotou (15206993) Abram Handly-Santana (15206996) Joan S. Brugge (9710515) Leonard Presta (15206999) John Glaspy (15207002) Dennis J. Slamon (15047067) |
| author2_role | author author author author author author author author author author author author author author author author author author author |
| author_facet | Martina S.J. McDermott (15206951) Neil A. O'Brien (15206954) Benjamin Hoffstrom (15206957) KeWei Gong (15206960) Ming Lu (15206963) Jun Zhang (15206966) Tong Luo (15206969) Min Liang (15206972) Weiping Jia (15206975) Jenny J. Hong (15206978) Kevin Chau (15206981) Simon Davenport (15206984) Bin Xie (15206987) Michael F. Press (15206990) Richard Panayiotou (15206993) Abram Handly-Santana (15206996) Joan S. Brugge (9710515) Leonard Presta (15206999) John Glaspy (15207002) Dennis J. Slamon (15047067) |
| author_role | author |
| dc.creator.none.fl_str_mv | Martina S.J. McDermott (15206951) Neil A. O'Brien (15206954) Benjamin Hoffstrom (15206957) KeWei Gong (15206960) Ming Lu (15206963) Jun Zhang (15206966) Tong Luo (15206969) Min Liang (15206972) Weiping Jia (15206975) Jenny J. Hong (15206978) Kevin Chau (15206981) Simon Davenport (15206984) Bin Xie (15206987) Michael F. Press (15206990) Richard Panayiotou (15206993) Abram Handly-Santana (15206996) Joan S. Brugge (9710515) Leonard Presta (15206999) John Glaspy (15207002) Dennis J. Slamon (15047067) |
| dc.date.none.fl_str_mv | 2025-11-25T13:00:34Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706655 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_S4_from_Preclinical_Efficacy_of_the_Antibody_Drug_Conjugate_CLDN6_23-ADC_for_the_Treatment_of_CLDN6-Positive_Solid_Tumors/30706655 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research |
| dc.title.none.fl_str_mv | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_e0662e56c6d0bc6d177e60bed94441dc |
| identifier_str_mv | 10.1158/1078-0432.30706655 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706655 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid TumorsMartina S.J. McDermott (15206951)Neil A. O'Brien (15206954)Benjamin Hoffstrom (15206957)KeWei Gong (15206960)Ming Lu (15206963)Jun Zhang (15206966)Tong Luo (15206969)Min Liang (15206972)Weiping Jia (15206975)Jenny J. Hong (15206978)Kevin Chau (15206981)Simon Davenport (15206984)Bin Xie (15206987)Michael F. Press (15206990)Richard Panayiotou (15206993)Abram Handly-Santana (15206996)Joan S. Brugge (9710515)Leonard Presta (15206999)John Glaspy (15207002)Dennis J. Slamon (15047067)CancerTherapeutic Research and DevelopmentBiological Agents & TherapiesAntibody-drug conjugatesGynecological CancersEndometrial cancerOvarian cancerTranslational Research<p>Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.</p>2025-11-25T13:00:34ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706655https://figshare.com/articles/figure/Figure_S4_from_Preclinical_Efficacy_of_the_Antibody_Drug_Conjugate_CLDN6_23-ADC_for_the_Treatment_of_CLDN6-Positive_Solid_Tumors/30706655CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307066552025-11-25T13:00:34Z |
| spellingShingle | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Martina S.J. McDermott (15206951) Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research |
| status_str | publishedVersion |
| title | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_full | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_fullStr | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_full_unstemmed | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_short | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_sort | Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| topic | Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research |